Clinical Trial Update: Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating trastuzumab plus irinotecan in HER2-positive metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED